Manfred Zoltobrocki
Corporate Officer/Principal en Lux Biosciences, Inc. .
Perfil
Manfred Zoltobrocki is currently the Managing Director-Germany at Lux Biosciences, Inc. He was previously the Chief Executive Officer at Epidauros Biotechnologie AG from 2003 to 2006.
He also held positions as Principal at Hoechst Marion Roussel SA and Hoechst Pharmaceuticals Ltd.
Additionally, he served as a Member-Supervisory Board at NascaCell Technologies AG.
From 1996 to 2002, he was the Vice President-Development at Aventis Pharma AG.
Dr. Zoltobrocki holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Cargos activos de Manfred Zoltobrocki
| Empresas | Cargo | Inicio |
|---|---|---|
Lux Biosciences, Inc.
 Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Corporate Officer/Principal | 21/10/2009 |
Antiguos cargos conocidos de Manfred Zoltobrocki.
| Empresas | Cargo | Fin |
|---|---|---|
NascaCell Technologies AG
 NascaCell Technologies AG Pharmaceuticals: MajorHealth Technology Nascacell Technologies Ag. offers improved, broadened and accelerated modern drug discovery. The company provides services like new generation of biomolecules with its Aptamer and Microbody technologies. Support is given to the customers in the areas of drug discovery and target validation. The company was founded in 2003 and is headquartered in Munich, Germany. | Director/Miembro de la Junta | 08/02/2011 |
Epidauros Biotechnologie AG
 Epidauros Biotechnologie AG Miscellaneous Commercial ServicesCommercial Services Part of AbbVie, Inc., Epidauros Biotechnologie AG is a German company that specializes in pharmacogenomics research. The company is based in Bernried, Germany. Epidauros Biotechnologie was acquired by Clinical Data BV from Deutsche Effecten & Wechsel Beteiligungs AG on August 23, 2007 for $11.83 million. | Presidente | 01/03/2006 |
| Aventis Pharma AG | Corporate Officer/Principal | 01/01/2002 |
| Hoechst Marion Roussel SA | Corporate Officer/Principal | - |
| Hoechst Pharmaceuticals Ltd. | Corporate Officer/Principal | - |
Formación de Manfred Zoltobrocki.
| Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 6 |
|---|---|
Lux Biosciences, Inc.
Lux Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Lux Biosciences, Inc. provides therapies for treatment of ophthalmic diseases. It develops and commercializes medications for ophthalmic diseases. The company was founded by Ulrich M. Grau, Eddy Anglade, Clarke A. Atwell and Sidney L. Weiss in 2006 and is headquartered in Jersey City, NJ. | Health Technology |
Epidauros Biotechnologie AG
Epidauros Biotechnologie AG Miscellaneous Commercial ServicesCommercial Services Part of AbbVie, Inc., Epidauros Biotechnologie AG is a German company that specializes in pharmacogenomics research. The company is based in Bernried, Germany. Epidauros Biotechnologie was acquired by Clinical Data BV from Deutsche Effecten & Wechsel Beteiligungs AG on August 23, 2007 for $11.83 million. | Commercial Services |
| Aventis Pharma AG | |
| Hoechst Pharmaceuticals Ltd. | |
| Hoechst Marion Roussel SA | Health Technology |
NascaCell Technologies AG
NascaCell Technologies AG Pharmaceuticals: MajorHealth Technology Nascacell Technologies Ag. offers improved, broadened and accelerated modern drug discovery. The company provides services like new generation of biomolecules with its Aptamer and Microbody technologies. Support is given to the customers in the areas of drug discovery and target validation. The company was founded in 2003 and is headquartered in Munich, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Manfred Zoltobrocki